Results 141 to 150 of about 15,200 (191)

Daratumumab-based quadruplet for patients with extramedullary multiple myeloma: Results from the Phase II prospective EMN19 study. [PDF]

Hemasphere
Beksac M, Fıratlı Tuglular T, Gay F, Mina R, Katodritou E, Unal A, Cavo M, Ozsan GH, van der Velden VHJ, Beverloo BH, Vermeulen M, van Duin M, Seval GC, Sevindik OG, Merante S, Manousou K, Sonneveld P, Zamagni E, Terpos E.   +18 more
europepmc   +1 more source

Assumptions Matter: The Long-Term Cost Analysis of IsaVRd vs DVRd. [PDF]

J Health Econ Outcomes Res
Lin F, Petitjean A, Sasane M.
europepmc   +1 more source

Bone marrow immune cell composition reflects multiple myeloma progression and affects treatment response. [PDF]

Blood Neoplasia
Corsale AM, Azgomi MS, Gigliotta E, Di Simone M, Pacelli P, Cioffi F, Bestoso E, Raspadori D, Gozzetti A, Solimando A, Tabares P, Beilhack A, Speciale M, Corsale G, Sciortino M, Aquilina C, Brucato F, Cea M, Zambello R, Garofano F, Biondo M, Buffa F, Caccamo N, Dieli F, Meraviglia S, Siragusa S, Botta C.   +26 more
europepmc   +1 more source

Daratumumab monotherapy in a patient with kappa light chain multiple myeloma and decompensated cirrhosis: a case report. [PDF]

Front Oncol
Yang X, Liu Z, Zhou Y, Zhang H, Yang M, Wang H.   +5 more
europepmc   +1 more source

Dreaming of a better future: drug development in myeloma. [PDF]

Blood Adv
Parikh R, Lonial S.
europepmc   +1 more source

NK92 cells stably transfected with CD16 are efficient against multiple myeloma cells <i>ex vivo</i> and <i>in vivo</i>, especially if combined with daratumumab. [PDF]

Oncoimmunology
Giraldos D, Galano-Frutos E, Cambronero-Arregui L, Beltrán Visiedo M, Romanos E, Reina-Ortiz C, Azaceta G, Martínez-Lázaro B, Menéndez-Jándula B, García-Romero A, Jiménez-Albericio FJ, Marzo I, Naval J, Anel A.   +13 more
europepmc   +1 more source

A Rare Case of Plasmablastic Lymphoma With Difficult Diagnosis and Treatment in a Cardiac Transplant Patient. [PDF]

Cureus
Gul O, Basit MA, Gul S, Gurunathan OS, Khalid M.   +4 more
europepmc   +1 more source

Donor-Derived Cell-Free DNA as a Marker for the Efficacy of Daratumumab in Patients With Antibody-Mediated Rejection Post-Heart Transplantation: A Case Series. [PDF]

Pediatr Transplant
Konduri A, Flynn KE, Huebschman A, Crandall B, Sinicropi N, Giacobbe B, Zamberlan M, Najor M, Cusick M, Lim HM, McCormick AD, Schumacher KR, Peng DM.   +12 more
europepmc   +1 more source

Chemo-RaST with bortezomib inhibits multiple myeloma relapse. [PDF]

Theranostics
Ghai A, Zheleznyak A, Egbulefu C, Blasi N, Black K, Tang R, Cooper ML, Vij K, Vij R, DiPersio J, Shokeen M, Achilefu S.   +11 more
europepmc   +1 more source